View article

Belatacept (BTC) is indicated as a renal-sparing, maintenance immunosuppressive agent in adults receiving renal transplant. Currently, the safety and efficacy of BTC in heart transplant (HT) recipients is unclear. The aim of this study is to describe 1) national trends in BTC use, and 2) single center BTC use and clinical outcomes among adult HT recipients.

We queried the Scientific Registry for Transplant Recipients (SRTR) database for all HT patients who received BTC as a component of their maintenance immunosuppression between 2011 and 2020. Temporal trends in use of BTC were examined to determine its indication and associated outcomes. Similarly, we queried the Emory Healthcare HT Database for all adult HT patients who received BTC as a component of their maintenance immunosuppression between 2019 and 2020. The frequency of renal dysfunction, acute rejection, and survival …